Geron Corporation (GERN)
USD 1.36
(-7.82%)
USD 1.36
(-7.82%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 146.12 Million USD | 32.15% |
| 2022 | 110.57 Million USD | 11.0% |
| 2021 | 99.61 Million USD | 66.64% |
| 2020 | 59.78 Million USD | 96.89% |
| 2019 | 30.36 Million USD | 302.09% |
| 2018 | 7.55 Million USD | 15.88% |
| 2017 | 6.51 Million USD | -17.19% |
| 2016 | 7.86 Million USD | 18.62% |
| 2015 | 6.63 Million USD | -84.13% |
| 2014 | 41.79 Million USD | 450.93% |
| 2013 | 7.58 Million USD | -46.37% |
| 2012 | 14.14 Million USD | 5.24% |
| 2011 | 13.44 Million USD | -67.09% |
| 2010 | 40.84 Million USD | 423.37% |
| 2009 | 7.8 Million USD | 0.54% |
| 2008 | 7.76 Million USD | -41.29% |
| 2007 | 13.22 Million USD | -71.8% |
| 2006 | 46.88 Million USD | 344.88% |
| 2005 | 10.53 Million USD | 7.42% |
| 2004 | 9.81 Million USD | -16.8% |
| 2003 | 11.79 Million USD | -61.88% |
| 2002 | 30.92 Million USD | -10.84% |
| 2001 | 34.68 Million USD | -30.78% |
| 2000 | 50.11 Million USD | 33.63% |
| 1999 | 37.5 Million USD | 220.51% |
| 1998 | 11.7 Million USD | 134.0% |
| 1997 | 5 Million USD | -3.85% |
| 1996 | 5.2 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 137.2 Million USD | -6.1% |
| 2024 Q2 | 142.7 Million USD | 4.01% |
| 2023 Q3 | 122.4 Million USD | 4.74% |
| 2023 Q2 | 116.86 Million USD | 18.26% |
| 2023 FY | 146.12 Million USD | 32.15% |
| 2023 Q1 | 98.82 Million USD | -10.63% |
| 2023 Q4 | 146.12 Million USD | 19.38% |
| 2022 Q3 | 124.43 Million USD | 29.47% |
| 2022 Q1 | 100.93 Million USD | 1.32% |
| 2022 Q2 | 96.11 Million USD | -4.78% |
| 2022 FY | 110.57 Million USD | 11.0% |
| 2022 Q4 | 110.57 Million USD | -11.14% |
| 2021 Q3 | 77.54 Million USD | 2.07% |
| 2021 Q1 | 57.44 Million USD | -3.91% |
| 2021 FY | 99.61 Million USD | 66.64% |
| 2021 Q4 | 99.61 Million USD | 28.47% |
| 2021 Q2 | 75.96 Million USD | 32.24% |
| 2020 FY | 59.78 Million USD | 96.89% |
| 2020 Q1 | 22.07 Million USD | -27.29% |
| 2020 Q2 | 24.13 Million USD | 9.32% |
| 2020 Q3 | 52.96 Million USD | 119.45% |
| 2020 Q4 | 59.78 Million USD | 12.88% |
| 2019 Q2 | 9.18 Million USD | 46.83% |
| 2019 Q3 | 11.86 Million USD | 29.2% |
| 2019 Q4 | 30.36 Million USD | 155.96% |
| 2019 FY | 30.36 Million USD | 302.09% |
| 2019 Q1 | 6.25 Million USD | -17.19% |
| 2018 Q2 | 4.9 Million USD | 11.86% |
| 2018 FY | 7.55 Million USD | 15.88% |
| 2018 Q1 | 4.38 Million USD | -32.7% |
| 2018 Q4 | 7.55 Million USD | 69.04% |
| 2018 Q3 | 4.46 Million USD | -8.93% |
| 2017 Q2 | 11.27 Million USD | -2.78% |
| 2017 Q1 | 11.59 Million USD | 47.36% |
| 2017 FY | 6.51 Million USD | -17.19% |
| 2017 Q4 | 6.51 Million USD | 9.15% |
| 2017 Q3 | 5.97 Million USD | -47.05% |
| 2016 Q4 | 7.86 Million USD | 7.51% |
| 2016 Q1 | 6.65 Million USD | 0.36% |
| 2016 Q2 | 7.11 Million USD | 6.8% |
| 2016 Q3 | 7.31 Million USD | 2.93% |
| 2016 FY | 7.86 Million USD | 18.62% |
| 2015 FY | 6.63 Million USD | -84.13% |
| 2015 Q4 | 6.63 Million USD | 8.31% |
| 2015 Q1 | 40.63 Million USD | -2.79% |
| 2015 Q2 | 40.72 Million USD | 0.23% |
| 2015 Q3 | 6.12 Million USD | -84.96% |
| 2014 Q4 | 41.79 Million USD | 491.3% |
| 2014 FY | 41.79 Million USD | 450.93% |
| 2014 Q2 | 4.75 Million USD | 5.31% |
| 2014 Q3 | 7.06 Million USD | 48.63% |
| 2014 Q1 | 4.51 Million USD | -40.48% |
| 2013 FY | 7.58 Million USD | -46.37% |
| 2013 Q2 | 5 Million USD | -26.34% |
| 2013 Q3 | 6.83 Million USD | 36.63% |
| 2013 Q4 | 7.58 Million USD | 10.97% |
| 2013 Q1 | 6.79 Million USD | -51.99% |
| 2012 FY | 14.14 Million USD | 5.24% |
| 2012 Q4 | 14.14 Million USD | 25.69% |
| 2012 Q3 | 11.25 Million USD | -6.14% |
| 2012 Q1 | 10.27 Million USD | -23.58% |
| 2012 Q2 | 11.99 Million USD | 16.72% |
| 2011 Q4 | 13.44 Million USD | 1.87% |
| 2011 FY | 13.44 Million USD | -67.09% |
| 2011 Q3 | 13.19 Million USD | 42.36% |
| 2011 Q2 | 9.27 Million USD | -0.99% |
| 2011 Q1 | 9.36 Million USD | -77.08% |
| 2010 FY | 40.84 Million USD | 423.37% |
| 2010 Q4 | 40.84 Million USD | 435.72% |
| 2010 Q3 | 7.62 Million USD | 11.92% |
| 2010 Q2 | 6.81 Million USD | -2.39% |
| 2010 Q1 | 6.98 Million USD | -10.57% |
| 2009 Q4 | 7.8 Million USD | -21.03% |
| 2009 Q1 | 7.75 Million USD | -0.05% |
| 2009 FY | 7.8 Million USD | 0.54% |
| 2009 Q2 | 10.41 Million USD | 34.22% |
| 2009 Q3 | 9.88 Million USD | -5.09% |
| 2008 Q3 | 8.6 Million USD | -0.44% |
| 2008 FY | 7.76 Million USD | -41.29% |
| 2008 Q2 | 8.64 Million USD | -2.28% |
| 2008 Q1 | 8.84 Million USD | -33.1% |
| 2008 Q4 | 7.76 Million USD | -9.8% |
| 2007 FY | 13.22 Million USD | -71.8% |
| 2007 Q2 | 15.18 Million USD | 37.86% |
| 2007 Q3 | 12.46 Million USD | -17.91% |
| 2007 Q4 | 13.22 Million USD | 6.07% |
| 2007 Q1 | 11.01 Million USD | -76.51% |
| 2006 Q2 | 6.24 Million USD | -20.02% |
| 2006 Q4 | 46.88 Million USD | 664.41% |
| 2006 Q3 | 6.13 Million USD | -1.86% |
| 2006 Q1 | 7.81 Million USD | -25.86% |
| 2006 FY | 46.88 Million USD | 344.88% |
| 2005 FY | 10.53 Million USD | 7.42% |
| 2005 Q4 | 10.53 Million USD | 0.93% |
| 2005 Q3 | 10.44 Million USD | 71.98% |
| 2005 Q2 | 6.07 Million USD | -0.96% |
| 2005 Q1 | 6.13 Million USD | -37.51% |
| 2004 Q2 | 9.98 Million USD | 21.43% |
| 2004 FY | 9.81 Million USD | -16.8% |
| 2004 Q3 | 8.46 Million USD | -15.18% |
| 2004 Q1 | 8.22 Million USD | -30.28% |
| 2004 Q4 | 9.81 Million USD | 15.85% |
| 2003 Q2 | 11.51 Million USD | -60.63% |
| 2003 Q4 | 11.79 Million USD | 13.51% |
| 2003 FY | 11.79 Million USD | -61.88% |
| 2003 Q3 | 10.38 Million USD | -9.8% |
| 2003 Q1 | 29.25 Million USD | -5.42% |
| 2002 Q2 | 32.8 Million USD | -2.5% |
| 2002 Q3 | 31.67 Million USD | -3.45% |
| 2002 Q1 | 33.64 Million USD | -3.0% |
| 2002 Q4 | 30.92 Million USD | -2.36% |
| 2002 FY | 30.92 Million USD | -10.84% |
| 2001 FY | 34.68 Million USD | -30.78% |
| 2001 Q2 | 49.79 Million USD | 1.96% |
| 2001 Q1 | 48.84 Million USD | -2.54% |
| 2001 Q3 | 49.52 Million USD | -0.55% |
| 2001 Q4 | 34.68 Million USD | -29.95% |
| 2000 Q3 | 52.74 Million USD | 0.17% |
| 2000 FY | 50.11 Million USD | 33.63% |
| 2000 Q4 | 50.11 Million USD | -4.98% |
| 2000 Q1 | 28.78 Million USD | -23.25% |
| 2000 Q2 | 52.65 Million USD | 82.94% |
| 1999 Q1 | 12.5 Million USD | 6.84% |
| 1999 Q3 | 42.9 Million USD | 28.06% |
| 1999 Q4 | 37.5 Million USD | -12.59% |
| 1999 FY | 37.5 Million USD | 220.51% |
| 1999 Q2 | 33.5 Million USD | 168.0% |
| 1998 Q1 | 3.4 Million USD | -32.0% |
| 1998 FY | 11.7 Million USD | 134.0% |
| 1998 Q4 | 11.7 Million USD | 192.5% |
| 1998 Q3 | 4 Million USD | -9.09% |
| 1998 Q2 | 4.4 Million USD | 29.41% |
| 1997 Q4 | 5 Million USD | -15.25% |
| 1997 Q1 | 4.4 Million USD | -15.38% |
| 1997 Q3 | 5.9 Million USD | -15.71% |
| 1997 FY | 5 Million USD | -3.85% |
| 1997 Q2 | 7 Million USD | 59.09% |
| 1996 Q1 | 3.4 Million USD | 0.0% |
| 1996 Q4 | 5.2 Million USD | 0.0% |
| 1996 FY | 5.2 Million USD | 0.0% |
| 1996 Q2 | 6.1 Million USD | 79.41% |
| 1996 Q3 | 5.2 Million USD | -14.75% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 56.481% |
| Alkermes plc | 933.53 Million USD | 84.347% |
| Agenus Inc. | 462.29 Million USD | 68.391% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.392% |
| Aptorum Group Limited | 5.25 Million USD | -2679.804% |
| Ardelyx, Inc. | 130.76 Million USD | -11.75% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 69.454% |
| Bicycle Therapeutics plc | 224.41 Million USD | 34.884% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -12.224% |
| ChromaDex Corporation | 26.5 Million USD | -451.256% |
| Chimerix, Inc. | 19.74 Million USD | -640.071% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -315.404% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -101.368% |
| CRISPR Therapeutics AG | 346.76 Million USD | 57.86% |
| Precision BioSciences, Inc. | 140.92 Million USD | -3.695% |
| Dyadic International, Inc. | 2.34 Million USD | -6143.007% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -798.524% |
| Fortress Biotech, Inc. | 165.93 Million USD | 11.939% |
| Lantern Pharma Inc. | 2.73 Million USD | -5233.721% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -104.431% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -4041.071% |
| Incyte Corporation | 1.59 Billion USD | 90.823% |
| IO Biotech, Inc. | 17.55 Million USD | -732.348% |
| Jaguar Health, Inc. | 45.86 Million USD | -218.595% |
| Novavax, Inc. | 2.57 Billion USD | 94.319% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -305.255% |
| Opthea Limited | 264.6 Million USD | 44.775% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -11.797% |
| ContextLogic Inc. | 206 Million USD | 29.065% |
| MiMedx Group, Inc. | 96.33 Million USD | -51.694% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -204.292% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -4040.881% |
| NextCure, Inc. | 14.99 Million USD | -874.375% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3515.215% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2088.513% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -212.645% |
| Vaxcyte, Inc. | 167.44 Million USD | 12.733% |
| PDS Biotechnology Corporation | 33.25 Million USD | -339.359% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 37.875% |
| Pharming Group N.V. | 244.07 Million USD | 40.13% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1125.692% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -14.348% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2111.606% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2111.606% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -77.268% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2099.714% |
| Acelyrin, Inc. | 86.35 Million USD | -69.221% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -11147.105% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -916.253% |
| Summit Therapeutics Inc. | 125.25 Million USD | -16.662% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1441.587% |
| Senti Biosciences, Inc. | 52.57 Million USD | -177.961% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -112.465% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 3.554% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -7370.706% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -10841.22% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 35.579% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1460.019% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 35.753% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 70.45% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1238.895% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -431.158% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1107.192% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 69.97% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3826.263% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -286.457% |
| MEI Pharma, Inc. | 8.35 Million USD | -1648.977% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -403.626% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 57.959% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -0.177% |
| Fortress Biotech, Inc. | 165.93 Million USD | 11.939% |
| Precigen, Inc. | 41.64 Million USD | -250.896% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -192.664% |
| AlloVir, Inc. | 45.01 Million USD | -224.618% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -12.115% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -6.043% |
| ImmuCell Corporation | 18.81 Million USD | -676.651% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -417.704% |
| Onconetix, Inc. | 23.18 Million USD | -530.377% |
| PureTech Health plc | 125.58 Million USD | -16.359% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1532.704% |
| Elevation Oncology, Inc. | 34.28 Million USD | -326.25% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5876.564% |
| Seer, Inc. | 39.36 Million USD | -271.21% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -136.321% |
| Innoviva, Inc. | 568.55 Million USD | 74.298% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -436.679% |
| ESSA Pharma Inc. | 3.49 Million USD | -4080.945% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2017.146% |
| GT Biopharma, Inc. | 6.63 Million USD | -2103.03% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 44.731% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 46.333% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -73.907% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1395.058% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -437.845% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -4429.984% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -98.093% |
| Aptose Biosciences Inc. | 15.8 Million USD | -824.345% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1223.652% |
| Soligenix, Inc. | 7.27 Million USD | -1908.645% |
| Century Therapeutics, Inc. | 175.94 Million USD | 16.945% |
| Kura Oncology, Inc. | 51.66 Million USD | -182.852% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -20.485% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3435.616% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2109.407% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 42.15% |
| Autolus Therapeutics plc | 263.9 Million USD | 44.629% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1294.076% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -64.444% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -211.578% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 58.587% |
| GRI Bio, Inc. | 2.69 Million USD | -5318.131% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -17949.618% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -369.998% |
| IGM Biosciences, Inc. | 220.17 Million USD | 33.632% |
| INmune Bio, Inc. | 18.86 Million USD | -674.716% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 43.026% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -448.487% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5275.466% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -4354.73% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -149.982% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -51.964% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 44.803% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 82.245% |
| Verastem, Inc. | 71.18 Million USD | -105.278% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -197.151% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -278.783% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -198.633% |
| Histogen Inc. | 5.69 Million USD | -2464.982% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3231.969% |
| Surrozen, Inc. | 8.14 Million USD | -1694.07% |
| Organovo Holdings, Inc. | 2.74 Million USD | -5217.576% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46458.316% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -159.874% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -784.975% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -185.946% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -17572.2% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -15.31% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1251.327% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 3.156% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -5504.437% |
| Apollomics, Inc. | 14.15 Million USD | -932.481% |
| Amarin Corporation plc | 279.58 Million USD | 47.735% |
| Mesoblast Limited | 188.79 Million USD | 22.601% |
| Turnstone Biologics Corp. | 14.14 Million USD | -932.846% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 19.172% |
| Synaptogenix, Inc. | 5.52 Million USD | -2542.695% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2098.06% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 14.098% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1607.651% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -8214.987% |
| Exelixis, Inc. | 678.44 Million USD | 78.461% |
| Better Therapeutics, Inc. | 23.84 Million USD | -512.897% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 10.923% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 75.408% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1268.204% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -8900.096% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -275.387% |
| Gritstone bio, Inc. | 125.91 Million USD | -16.048% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -895.687% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2771.639% |
| Avid Bioservices, Inc. | 275.66 Million USD | 46.992% |
| Insmed Incorporated | 1.66 Billion USD | 91.206% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1799.227% |
| MediWound Ltd. | 27.18 Million USD | -437.489% |
| OmniAb, Inc. | 87.4 Million USD | -67.193% |
| Alector, Inc. | 487.66 Million USD | 70.036% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 63.781% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -693.091% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -280.807% |
| Zai Lab Limited | 240.17 Million USD | 39.159% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 76.807% |
| Aura Biosciences, Inc. | 29.22 Million USD | -399.973% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -53.693% |
| Immunic, Inc. | 25.36 Million USD | -476.029% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -111.056% |
| Veracyte, Inc. | 93.71 Million USD | -55.92% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -5484.458% |
| FibroGen, Inc. | 585.72 Million USD | 75.052% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -740.632% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -22275.191% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2483.823% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.091% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1682.471% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -73.915% |
| TG Therapeutics, Inc. | 169.08 Million USD | 13.578% |
| Galecto, Inc. | 5.89 Million USD | -2378.409% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1663.967% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 94.419% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -406.998% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1057.808% |
| XBiotech Inc. | 8.39 Million USD | -1640.229% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -895.687% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -174.778% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 59.756% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -443.546% |
| Theravance Biopharma, Inc. | 169 Million USD | 13.536% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 87.979% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 70.799% |
| Vaxxinity, Inc. | 30.94 Million USD | -372.23% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 84.974% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2322.889% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 80.392% |
| NexImmune, Inc. | 5.08 Million USD | -2774.121% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -39245.547% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4652.332% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.944% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2735.199% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1860.27% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -455.743% |
| Ainos, Inc. | 7.39 Million USD | -1876.232% |
| Pluri Inc. | 34.11 Million USD | -328.374% |
| Prothena Corporation plc | 135.01 Million USD | -8.229% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 39.891% |
| Celularity Inc. | 102.92 Million USD | -41.969% |
| Rallybio Corporation | 9.43 Million USD | -1448.612% |
| Cue Biopharma, Inc. | 24.44 Million USD | -497.779% |
| MeiraGTx Holdings plc | 319.99 Million USD | 54.334% |
| Omeros Corporation | 403.25 Million USD | 63.763% |
| Humacyte, Inc. | 114.67 Million USD | -27.425% |
| Immunocore Holdings plc | 228.15 Million USD | 35.954% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2897.477% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -90.418% |
| Blueprint Medicines Corporation | 918.64 Million USD | 84.093% |
| CalciMedica, Inc. | 4.02 Million USD | -3527.781% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -737.308% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 5.2% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -70.277% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 47.397% |
| Pulmatrix, Inc. | 15.96 Million USD | -815.411% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -826.438% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -493.867% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 41.738% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -187.731% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 87.93% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -359.765% |
| Nutriband Inc. | 1.07 Million USD | -13443.834% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1274.278% |
| Vor Biopharma Inc. | 59.1 Million USD | -147.237% |
| Roivant Sciences Ltd. | 773.95 Million USD | 81.119% |
| Evogene Ltd. | 17.99 Million USD | -712.268% |
| ProKidney Corp. | 29.21 Million USD | -400.161% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -103.013% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -20627.734% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 92.264% |
| CorMedix Inc. | 11.91 Million USD | -1126.152% |
| BioLineRx Ltd. | 50.7 Million USD | -188.208% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 2.229% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -65.225% |
| Atai Life Sciences N.V. | 49.16 Million USD | -197.236% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -369.073% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -713.534% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -17.243% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2484.489% |
| MediciNova, Inc. | 3.89 Million USD | -3654.979% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -699.426% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9614.334% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4051.476% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 63.216% |
| Biomea Fusion, Inc. | 30.69 Million USD | -376.139% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 94.631% |
| Mereo BioPharma Group plc | 15.96 Million USD | -815.468% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -368.341% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -149.007% |
| Absci Corporation | 58.3 Million USD | -150.629% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -667.151% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -355.764% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -98.031% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -67.035% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -332.712% |
| Allakos Inc. | 74.79 Million USD | -95.375% |
| Imunon, Inc. | 8.53 Million USD | -1613.009% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -549.424% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -27.275% |
| BioAtla, Inc. | 48.98 Million USD | -198.304% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1268.204% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -5158.258% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -11.886% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -927.977% |
| XOMA Corporation | 145.58 Million USD | -0.376% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -334.062% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -112.521% |
| aTyr Pharma, Inc. | 31.59 Million USD | -362.471% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -136.363% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -224.979% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -201.903% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4991.533% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1691.207% |
| Akari Therapeutics, Plc | 4.58 Million USD | -3087.762% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -724.034% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 91.141% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -36078.288% |
| UroGen Pharma Ltd. | 243.52 Million USD | 39.995% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 54.49% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -5191.47% |
| Orgenesis Inc. | 35.53 Million USD | -311.22% |
| Entera Bio Ltd. | 1.37 Million USD | -10496.592% |
| GH Research PLC | 6.7 Million USD | -2080.675% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2048.926% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -676.198% |
| Xencor, Inc. | 283.55 Million USD | 48.467% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4794.27% |
| Replimune Group, Inc. | 113.21 Million USD | -29.071% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3789.33% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -41.145% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -36078.288% |
| Portage Biotech Inc. | 4.45 Million USD | -3183.753% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9614.334% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -533.957% |
| OncoCyte Corporation | 49.29 Million USD | -196.416% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3432.364% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -18223.502% |
| Purple Biotech Ltd. | 10 Million USD | -1360.54% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2425.527% |
| scPharmaceuticals Inc. | 57.26 Million USD | -155.195% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1079.583% |
| HilleVax, Inc. | 78.9 Million USD | -85.184% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2793.604% |
| Tharimmune, Inc. | 1.81 Million USD | -7950.87% |
| Genprex, Inc. | 3.25 Million USD | -4390.401% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -438.836% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2690.814% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -70835.437% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -40655.213% |
| OKYO Pharma Limited | 7.42 Million USD | -1869.142% |
| Savara Inc. | 37.19 Million USD | -292.899% |
| Curis, Inc. | 57.61 Million USD | -153.64% |
| Daré Bioscience, Inc. | 26.32 Million USD | -454.986% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -272.775% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -10019.598% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -601.893% |
| BeiGene, Ltd. | 2.23 Billion USD | 93.458% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -586.371% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 44.311% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -586.881% |
| Erasca, Inc. | 78.61 Million USD | -85.886% |
| bluebird bio, Inc. | 424.62 Million USD | 65.587% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22200.886% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.269% |
| DBV Technologies S.A. | 42.8 Million USD | -241.418% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22200.886% |
| Moderna, Inc. | 4.57 Billion USD | 96.804% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1989.021% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -8724.094% |
| Molecular Templates, Inc. | 31.17 Million USD | -368.792% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -756.046% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 75.153% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -17.366% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -432.591% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -300.831% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -162.653% |
| MacroGenics, Inc. | 154.2 Million USD | 5.24% |
| RenovoRx, Inc. | 4.46 Million USD | -3171.988% |
| Adicet Bio, Inc. | 37.12 Million USD | -293.661% |
| Prime Medicine, Inc. | 60.78 Million USD | -140.42% |
| Aditxt, Inc. | 28.53 Million USD | -412.159% |
| Adagene Inc. | 45.16 Million USD | -223.509% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80766.736% |
| Quantum-Si incorporated | 26.63 Million USD | -448.71% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 79.052% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4702.957% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -27.11% |
| SciSparc Ltd. | 1.59 Million USD | -9061.567% |
| Vericel Corporation | 127.7 Million USD | -14.425% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2525.872% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -71.193% |
| Generation Bio Co. | 171.63 Million USD | 14.859% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1165.169% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -249.327% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 42.173% |
| Invivyd, Inc. | 51.71 Million USD | -182.573% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -58.873% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2146.293% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -93.556% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -14212.145% |
| 2seventy bio, Inc. | 310.12 Million USD | 52.881% |
| ADMA Biologics, Inc. | 193.97 Million USD | 24.667% |
| Clene Inc. | 38.95 Million USD | -275.156% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -304.416% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 43.136% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4051.476% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 23.197% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1099.762% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 26.318% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1098.273% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -203.729% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -176.541% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 60.491% |
| Evaxion Biotech A/S | 17.61 Million USD | -729.443% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 9.198% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 4.608% |
| Trevena, Inc. | 48.26 Million USD | -202.779% |
| Surrozen, Inc. | 8.14 Million USD | -1694.07% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -576.671% |
| Cingulate Inc. | 10.36 Million USD | -1310.375% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -5213.709% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -291.845% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3974.339% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1011.232% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 53.932% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -488.06% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3947.83% |
| Kronos Bio, Inc. | 54.2 Million USD | -169.602% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -210.624% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -542.042% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -628.05% |
| Statera Biopharma, Inc. | 22.67 Million USD | -544.4% |
| ImmunityBio, Inc. | 1.09 Billion USD | 86.599% |
| Korro Bio, Inc. | 51.75 Million USD | -182.36% |
| Kineta, Inc. | 7.22 Million USD | -1923.359% |
| BioVie Inc. | 9.7 Million USD | -1406.133% |
| Codexis, Inc. | 49.94 Million USD | -192.57% |
| Celularity Inc. | 102.92 Million USD | -41.969% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -51.825% |
| Celcuity Inc. | 51.45 Million USD | -184.017% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -42231.848% |
| Cibus, Inc. | 206.11 Million USD | 29.105% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -244.031% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -454.793% |
| IN8bio, Inc. | 8.77 Million USD | -1565.834% |
| Kodiak Sciences Inc. | 213.59 Million USD | 31.586% |
| Annexon, Inc. | 47.11 Million USD | -210.13% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -63.196% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -51.628% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -967.478% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.387% |
| Eyenovia, Inc. | 19.78 Million USD | -638.751% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 17.482% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1802.448% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -506.361% |
| Arcellx, Inc. | 339.75 Million USD | 56.99% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1128.164% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 40.487% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1428.046% |
| Moolec Science SA | 13.94 Million USD | -947.854% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -238.633% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -189.177% |
| Royalty Pharma plc | 6.29 Billion USD | 97.68% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -267.375% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -49534.518% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5839.441% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 22.748% |
| Humacyte, Inc. | 114.67 Million USD | -27.425% |
| Structure Therapeutics Inc. | 29.05 Million USD | -403.002% |
| 89bio, Inc. | 59.96 Million USD | -143.695% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -452.194% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -12117.977% |
| Genelux Corporation | 8.42 Million USD | -1635.475% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2031.374% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -7.195% |
| Notable Labs, Ltd. | 4.42 Million USD | -3200.813% |
| Liquidia Corporation | 73.13 Million USD | -99.796% |
| Mustang Bio, Inc. | 17.61 Million USD | -729.372% |
| Immunovant, Inc. | 48.95 Million USD | -198.492% |
| Quantum-Si incorporated | 26.63 Million USD | -448.71% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -280.708% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4609.217% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -97.841% |
| Acasti Pharma Inc. | 11.55 Million USD | -1164.403% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -546.359% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5275.466% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -296.255% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -10622.226% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2297.096% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -488.391% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -530.292% |
| PepGen Inc. | 34.63 Million USD | -321.954% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1103.286% |
| United Therapeutics Corporation | 1.18 Billion USD | 87.639% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1992.311% |
| Solid Biosciences Inc. | 38.45 Million USD | -279.965% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1607.651% |
| Immuneering Corporation | 12 Million USD | -1116.878% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46458.316% |
| Silo Pharma, Inc. | 1.56 Million USD | -9211.782% |
| Belite Bio, Inc | 4.21 Million USD | -3370.126% |
| XOMA Corporation | 145.58 Million USD | -0.376% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5918.41% |
| Bionomics Limited | 10.15 Million USD | -1338.439% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -579.945% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -537.747% |
| uniQure N.V. | 624.01 Million USD | 76.583% |
| Cassava Sciences, Inc. | 14.19 Million USD | -929.426% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80766.736% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 14.136% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3886.007% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -55976.951% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2065.807% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1802.448% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -740.632% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1282.731% |
| Altimmune, Inc. | 16.54 Million USD | -783.423% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 76.344% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -537.747% |
| Compugen Ltd. | 55.77 Million USD | -161.994% |
| Peak Bio, Inc. | 20.75 Million USD | -604.112% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -32.286% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2844.921% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 7.423% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -94.385% |
| Zura Bio Limited | 21.29 Million USD | -586.3% |
| PolyPid Ltd. | 17.46 Million USD | -736.541% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -30.007% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -94.385% |
| Instil Bio, Inc. | 99.8 Million USD | -46.418% |
| argenx SE | 444.95 Million USD | 67.159% |
| Immunome, Inc. | 28.65 Million USD | -409.9% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1652.753% |
| Verona Pharma plc | 58.84 Million USD | -148.342% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -909.652% |
| Shattuck Labs, Inc. | 14.85 Million USD | -883.424% |
| CervoMed Inc. | 2.59 Million USD | -5529.478% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2898.092% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1047.354% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1287.062% |
| Moolec Science SA | 13.94 Million USD | -947.854% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -6135.406% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -162.841% |
| AnaptysBio, Inc. | 364.28 Million USD | 59.887% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1122.206% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1052.058% |
| NeurAxis, Inc. | 1.91 Million USD | -7539.673% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -275.378% |
| Lumos Pharma, Inc. | 13.33 Million USD | -995.98% |
| Achilles Therapeutics plc | 19.08 Million USD | -665.584% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -909.652% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2612.481% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -519.497% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -542.042% |
| Nutriband Inc. | 1.07 Million USD | -13443.834% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -377.57% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -907.008% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 63.584% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -349.995% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1019.825% |
| Palisade Bio, Inc. | 2.73 Million USD | -5235.049% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2681.782% |
| Beam Therapeutics Inc. | 478.38 Million USD | 69.454% |
| Neurogene Inc. | 36.54 Million USD | -299.811% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 63.28% |
| AEON Biopharma, Inc. | 159.88 Million USD | 8.607% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -206.667% |
| Sesen Bio, Inc. | 30.98 Million USD | -371.621% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -462.871% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1822.163% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 25.346% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 23.915% |
| Athira Pharma, Inc. | 30.05 Million USD | -386.166% |
| Vaccinex, Inc. | 5.94 Million USD | -2359.222% |
| HCW Biologics Inc. | 15.05 Million USD | -870.818% |
| XOMA Corporation | 145.58 Million USD | -0.376% |
| Nektar Therapeutics | 267.04 Million USD | 45.28% |
| Arvinas, Inc. | 644.6 Million USD | 77.331% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -724.034% |
| Merus N.V. | 102.15 Million USD | -43.05% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 0.152% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -53.624% |
| Rezolute, Inc. | 11.73 Million USD | -1145.33% |
| Clene Inc. | 38.95 Million USD | -275.156% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -5031.981% |
| BeyondSpring Inc. | 48.26 Million USD | -202.735% |
| Synlogic, Inc. | 32.89 Million USD | -344.223% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -899.979% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -8842.901% |
| Peak Bio, Inc. | 20.75 Million USD | -604.112% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -130.27% |
| Krystal Biotech, Inc. | 39.71 Million USD | -267.948% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 61.203% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -46.76% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -33668.944% |
| MannKind Corporation | 721.36 Million USD | 79.743% |
| Ikena Oncology, Inc. | 22.33 Million USD | -554.251% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6905.129% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -42.438% |
| Gossamer Bio, Inc. | 249.14 Million USD | 41.349% |
| CohBar, Inc. | 1.03 Million USD | -14037.154% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1267.078% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -667.151% |
| Legend Biotech Corporation | 589.93 Million USD | 75.23% |
| Mural Oncology plc | 37.92 Million USD | -285.275% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -10.171% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -6266.269% |
| Disc Medicine, Inc. | 22.87 Million USD | -538.807% |
| Champions Oncology, Inc. | 28.03 Million USD | -421.231% |
| REGENXBIO Inc. | 262.22 Million USD | 44.275% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -4249.857% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1065.845% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -987.932% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -589.116% |
| Vaxart, Inc. | 34.02 Million USD | -329.47% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -616.686% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -412.153% |
| Cellectis S.A. | 249.57 Million USD | 41.45% |
| Longeveron Inc. | 5.33 Million USD | -2637.999% |
| Repare Therapeutics Inc. | 41.81 Million USD | -249.427% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 93.925% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -142.06% |
| Revolution Medicines, Inc. | 262.39 Million USD | 44.311% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -6835.311% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1594.03% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1138.259% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -940.568% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -6693.445% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.162% |
| Denali Therapeutics Inc. | 122.96 Million USD | -18.838% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2525.872% |
| Veru Inc. | 32.81 Million USD | -345.337% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2027.34% |
| Cingulate Inc. | 10.36 Million USD | -1310.375% |
| Passage Bio, Inc. | 39.26 Million USD | -272.184% |
| Context Therapeutics Inc. | 4.19 Million USD | -3386.091% |
| Exicure, Inc. | 8.54 Million USD | -1609.288% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -395.211% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1293.544% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -562.978% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 10.344% |
| Nuvalent, Inc. | 31.82 Million USD | -359.187% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2197.007% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -131.867% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -711.817% |
| OmniAb, Inc. | 87.4 Million USD | -67.193% |
| Anew Medical, Inc. | 8.24 Million USD | -1672.999% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -281.641% |
| Lipocine Inc. | 2.63 Million USD | -5452.72% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -456.208% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -263.392% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -448.487% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -69.611% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2605.555% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -76.595% |
| Ocugen, Inc. | 23.98 Million USD | -509.294% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -214.881% |
| Q32 Bio Inc. | 233.12 Million USD | 37.319% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1511.813% |
| Alumis Inc. Common Stock | 53.5 Million USD | -173.124% |
| Equillium, Inc. | 27.95 Million USD | -422.685% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 29.268% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2497.045% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2282.647% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 7.118% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -110.458% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1365.05% |
| Dominari Holdings Inc. | 4.63 Million USD | -3052.686% |
| Edesa Biotech, Inc. | 1.84 Million USD | -7834.626% |
| vTv Therapeutics Inc. | 29.56 Million USD | -394.223% |
| Bio-Techne Corporation | 744.34 Million USD | 80.368% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -15.883% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 57.577% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -260.14% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -404.634% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -58.215% |
| Nkarta, Inc. | 105.6 Million USD | -38.378% |
| BioCardia, Inc. | 4.59 Million USD | -3083.595% |
| Iterum Therapeutics plc | 32.66 Million USD | -347.391% |